Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
2
Molnupiravir, an Oral Antiviral Treatment for COVID-19
3
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
4
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
Drag to adjust the number of frozen columns
Author
Journal
Publication Date
DOI Link
Brief Summary
Abstract
Section
Topic
Level of Evidence
Journal Impact Factor
Key literature?
Bernal AJ, Gomes da Silva MM, Musungaie DB, et al
New England Journal of Medicine
12/16/2021
doi.org/10.1056/NEJMoa2116044
MOVe-OUT was a phase 3, double-blind trial that randomized high risk outpatients with symptomatic COVID-19 within 5 days of symptom onset to receive molnupiravir 800 mg twice daily for 5 days (n=716) or placebo (n=717). The molnupiravir arm resulted in fewer hospitalizations or deaths through day 29 compared to the placebo arm (6.8% [48 of 709] vs. 9.7% [68 of 699]; difference, -3.0 percentage points, 95% CI -5.9 to -0.1)
BACKGROUND
Therapeutics
Molnupiravir
Level 1- Homogenous Metanalyses or RCTs
Fischer W, Eron JJ, Holman W, et al
medRxiv
6/17/2021
doi.org/10.1101/2021.06.17.21258639
Phase 2a trial that randomized outpatients with SARS-CoV-2 and symptom onset within 7 days to receive molnupiravir 200 mg (n=23), 400 mg (n=62). or 800 mg (n=55) twice daily, or placebo (n=62). By day 3, molnupiravir 800 mg led to lower virus isolation than placebo (1.9% vs. 16.7%, p=0.016), while 200 mg and 400 mg dosages did not result in a statistically significant difference. By day 5, both molnupiravir 800 mg and 400 mg groups had no participants with isolated virus (compared to 11.1% in th